Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi

Nonalcoholic fatty liver disease and renin-angiotensin-aldosteron system (RAAS) blockers in patients with chronic kidney disease (CROSBI ID 614981)

Prilog sa skupa u časopisu | sažetak izlaganja sa skupa | domaća recenzija

Mikolašević, Ivana ; Lukenda, Vesna ; Rački, Sanjin ; Anić, Kata ; Štimac, Davor ; Orlić, Lidija Nonalcoholic fatty liver disease and renin-angiotensin-aldosteron system (RAAS) blockers in patients with chronic kidney disease // Liječnički vjesnik : glasilo Hrvatskoga liječničkog zbora / Anić, Branimir (ur.). 2014. str. 20-20

Podaci o odgovornosti

Mikolašević, Ivana ; Lukenda, Vesna ; Rački, Sanjin ; Anić, Kata ; Štimac, Davor ; Orlić, Lidija

engleski

Nonalcoholic fatty liver disease and renin-angiotensin-aldosteron system (RAAS) blockers in patients with chronic kidney disease

Recent data suggest that the renin-angiotensin-aldosteron system (RAAS) may be of importance in the pathogenesis of nonalcoholic fatty liver disease (NAFLD). We were interested to investigate whether the therapy with RAAS blockers in patients with different stages of chronic kidney disease (CKD) has any effect on steatosis and fibrosis grade ; NAFLD documented by transient elastography (TE) (Fibroscan®-CAP). Of 191 patients with various stages of CKD there were 61 patients with CKD grade III and IV, 62 patients with End-Stage renal disease treated with chronic haemodialysis and 68 renal transplant recipients. Liver stiffness was selected as the parameter to quantify liver fibrosis. Furthermore the Controlled Attenuation Parameter (CAP) was used to detect and quantify liver steatosis with the help of TE. CKD patients (p=0.005) and CKD-NAFLD patients (p=0.0005) with ACE-I or ARBs had statistically significant lower degree of liver stiffness in comparison to those without these medications (p=0.005). Also, we were interested to explore is there any difference in fibrosis and steatosis grade due to use of ACE-I or ARBs. We didn' t found statistically significant differences between those two subgroups of patients with respect to liver steatosis/fibrosis. Based on our results, RAAS blockers could be an attractive option for the management of NAFLD. TE provides the opportunity of non-invasive screening for NAFLD in CKD patients, as well as an opportunity of non-invasive monitoring of ACE-I/ARBs treatment efficiency in the CKD patients with NAFLD.

renin-angiotensin-aldosteron system; nonalcoholic fatty liver disease (NAFLD); chronic kidney disease; transient elastography; non-invasive screening

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o prilogu

20-20.

2014.

nije evidentirano

objavljeno

Podaci o matičnoj publikaciji

Liječnički vjesnik : glasilo Hrvatskoga liječničkog zbora

Anić, Branimir

Zagreb:

0024-3477

Podaci o skupu

Hrvatski internistički kongres s međunarodnim sudjelovanjem (8 ; 2014)

poster

03.10.2014-05.10.2014

Opatija, Hrvatska

Povezanost rada

Kliničke medicinske znanosti

Indeksiranost